Auris Medical Holding Ltd.

NASDAQ: EARSHealthcare / Biotechnology / Switzerland
2.76-0.0800-2.82%Vol 54 1331Y Perf -82.47%
Jun 24th, 2019 16:00
BID2.72 ASK2.77
Open2.82 Previous Close2.84
Pre-Market- After-Trading2.74
 - -%  -0.02 -0.72%
Target Price
2.50 
Analyst Rating
— 0.00
Potencial %
-9.42 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12M
-/-/- 
Income Ranking
 —    -
Market Cap (mil)5 
Earnings Rating
Neutral
Price Range Ratio 52wk %
0.95 
Earnings Date
25th Jun 2019

Today's Price Range

2.702.82

52wk Range

2.4139.40

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Month
3.76%
3 Months
-61.31%
6 Months
-64.16%
1 Year
-82.47%
3 Years
-92.77%
5 Years
-

Name / TickerPriceChg.Chg.%
EARS2.76-0.0800-2.82
AAPL198.58-0.2000-0.10
GOOG1 115.52-6.3600-0.57
MSFT137.780.81000.59
XOM76.95-0.7400-0.95
WFC46.27-0.6200-1.32
JNJ143.060.97000.68
FB192.601.46000.76
GE10.28-0.2000-1.91
JPM108.66-0.7800-0.71
Earnings HistoryEstimateReportedSurprise %
Q04 2018--2.40-
Q03 2018--2.80-
Q04 2017--20.20-
Q03 2017-2.00-1.5025.00
Q02 2017-2.10-1.2042.86
Q01 2017-0.10-0.22-120.00
Q04 2016-0.22-0.1627.27
Q03 2016-0.28-0.2317.86
Earnings Per EndEstimateRevision %Trend
9/2017 QR-0.200.00-
12/2017 QR-0.140.00-
12/2019 FY-2.5877.76Positive
12/2020 FY-3.7777.56Positive
Next Report Date25th Jun 2019
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume54 133
Shares Outstanding (in ths.)1 875
Trades Count136
Dollar Volume113 520
Avg. Volume171 451
Avg. Weekly Volume148 843
Avg. Monthly Volume364 686
Avg. Quarterly Volume247 532
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
1 (100.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
0 (0.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Rating--Strong Buy
1.00

Auris Medical Holding Ltd.

Auris Medical Holding Ltd is a clinical-stage biopharmaceutical company. The company develops novel products for the treatment of inner ear disorders. It has two projects in advanced clinical development Keyzilen for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. It is developing Keyzilen for the treatment of acute inner ear (peripheral) tinnitus following traumatic cochlear injury or otitis media (middle ear infection). Keyzilen contains Esketamine hydrochloride, an N-Methyl-D-Aspartate (NMDA) receptor antagonist, formulated in a biocompatible and fully biodegradable gel. It is also developing AM-111 for the treatment of acute inner ear (sensorineural) hearing loss (ASNHL).

CEO: Thomas Meyer

Teplephone: +41 417297194

Address: Bahnhofstrasse 21, Zug 6300, , CHE

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

65%35%

News